CA-PATIENT-SAFETY
4.4.2022 14:02:12 CEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF) will host the 8th annual World Patient Safety, Science and Technology Summit (WPSSTS) virtually April 29 and April 30, 2022. The event is co-convened by the American Society of Anesthesiologists, the European Society of Anesthesiology and Intensive Care, the International Society for Quality in Health Care and the World Federation of Societies of Anaesthesiologists. Creating a powerful forum for industry leaders and healthcare organizations to confront leading patient safety issues with actionable ideas and innovations to transform the continuum of care, the event supports PSMF’s mission to reach zero preventable patient harm and death across the world by 2030.
“The last two years have been taxing on the healthcare sector to say the least. The global pandemic placed relentless stress on health systems and medical personnel, which resulted in an increase in preventable medical errors,” said Dr. Michael Ramsay, CEO of PSMF. “Our organization is eager to bring key stakeholders together to help develop solutions to dramatically improve patient safety and eliminate preventable patient harm and death.”
The summit will include a fireside chat with patient safety luminaries, seven keynote addresses, as well as five panel sessions covering various topics in patient safety led by esteemed healthcare leaders. This year’s WPSSTS sessions focus on key issues impacting the healthcare industry, including:
- Overcoming Obstacles for Applying High Reliability Principles in Healthcare
- Embracing the Science of Human Factors to Unleash Safety Innovation in Healthcare
- Patient Advocacy: The Compass for Innovation
- How Regulation Can Support Quality and Value in Healthcare
- Healthcare Safety During the Pandemic
Attendees will have the opportunity to network with top hospital executives, patients and family members who have been impacted by medical error, public policymakers and government officials, as well as leaders across the healthcare continuum. Keynote speakers include:
- Randall Clark, MD, FASA, president of the American Society of Anesthesiologists
- Edoardo de Robertis, MD, PhD and president of the European Society of Anaesthesiology and Intensive Care (ESAIC)
- Neelam Dhingra-Kumar, MD, unit head of the WHO Patient Safety Flagship
- Carsten Engel, MD, CEO of the International Society for Quality in Health Care
- Joe Kiani, founder & immediate past chairman of the Patient Safety Movement Foundation, as well as founder, chairman & CEO of Masimo
- Peter Pronovost, MD, PhD, chief clinical transformation officer at University Hospitals
- Thomas Zeltner MD, chairman of the WHO Foundation, Geneva (Switzerland) and deputy chair of the University Council of the Medical University of Vienna (Austria)
The summit is open to anyone interested in actively planning solutions around the leading patient safety challenges that cause preventable patient deaths in hospitals and healthcare organizations worldwide. Discounted registration is offered for students, patients and family members. To register for the 2022 WPSSTS or to learn more about the event, visit: https://patient.sm/WPSSTS .
About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005206/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
